Boston Scientific Corporation (BSX)
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Here is how Boston Scientific (BSX) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
3 Reasons Growth Investors Will Love Boston Scientific (BSX)
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Boston Scientific Corporation Is Expensive But Worth It
Boston Scientific is a 'forever stock' due to management foresight, robust R&D, and leadership in AI-driven medical devices. Despite a weak valuation grade, its strong financials, global expansion, and AI integration justify a long-term buy rating. Key risks include regulatory changes, insider selling, and potential revenue impacts from federal healthcare cutbacks; buy on dips is advised.
Investors Heavily Search Boston Scientific Corporation (BSX): Here is What You Need to Know
Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up
BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.
Boston Scientific Corporation (BSX) Q2 2025 Earnings Call Transcript
Boston Scientific Corporation (NYSE:BSX ) Q2 2025 Earnings Conference Call July 23, 2025 8:00 AM ET Company Participants Jonathan R. Monson - Executive VP & CFO Kenneth M.
Boston Scientific (BSX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Boston Scientific (BSX) Q2 Earnings and Revenues Surpass Estimates
Boston Scientific (BSX) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.62 per share a year ago.
How To Trade Boston Scientific Stock Ahead Of Its Upcoming Earnings?
Boston Scientific (NYSE:BSX) is set to announce its earnings on Wednesday, July 23, 2025. In the last five years, BSX stock has shown a positive return on the day after earnings announcements in 60% of cases.
